Hormonal
Metformin produces moderate weight loss (3-5% reduction) in adults with T2DM or obesity, primarily by lowering hunger and reducing calorie intake, and can prevent weight gain associated with antipsychotic medications.
Metformin is a cornerstone treatment for Type 2 Diabetes that also offers moderate weight loss benefits (typically 3-5% body weight reduction). It works by reducing appetite and calorie intake. It is particularly useful for patients who need to counteract weight gain caused by other medications, such as antipsychotics. While gastrointestinal side effects are common, they often subside, and the long-term weight and metabolic benefits are substantial.
Metformin mostly causes weight loss by lowering hunger and resulting in consuming less calories... metformin’s impact on weight gain brought on by these medications has been studied... metformin significantly decreased BMI
Why this rating
Supported by large-scale trials like the Diabetes Prevention Program (DPP) and multiple meta-analyses.
Source
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad et al. · Life · 2023
DOI 10.3390/life13041012
More from this paper
- GLP-1 receptor agonists (specifically liraglutide and semaglutide) produce the greatest weight loss among anti-diabetic medications, with effects classified as strong (>5% reduction), whereas DPP-4 inhibitors and alpha-glucosidase inhibitors (acarbose) produce only mild or neutral effects.Good
- SGLT-2 inhibitors and DPP-4 inhibitors produce modest or neutral weight loss effects, respectively, making them less effective for weight management compared to GLP-1 agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →